Valerio Therapeutics (Euronext Growth Paris: ALVIO), a Lexington, MA- and Paris, France based clinical-stage biotechnology company, acquired Emglev Therapeutics, a Paris, France-based single-domain antibody-based therapeutics company.
The amount of the deal was not disclosed.
The acquisition is structured through a sale of shares paid in cash and a contribution in kind of Emglev shares against Valour Bio shares. As a result, shareholders of Emglev became shareholders of Valour Bio. The acquisition and operation of Emglev will enable new scientific and financial synergies to be created within the Valerio Group, with the first benefits for Valerio Therapeutics and Valour Bio expected to materialize in Q1 2025.
Led by CEO Christelle Masdeu, Emglev has developed sdAb technology that has broad applications in therapeutic areas such as inflammatory disorders, autoimmune diseases and cancer, as well as for the development of various treatment modalities including sdAb drug and radio-conjugates, bispecific T-cell engagers, blocking and binding sdAb or CAR-T sdAb drugs to name a few.
Led by President and CEO Dr. Shefali Agarwal, Valerio Therapeutics is a clinical-stage biotechnology company developing oncology drugs targeting tumor DNA-binding functions through mechanisms of action in the sought-after field of DNA damage response (DDR). It is focused on bringing early-stage compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
